

Table 1. General Characteristics.

Characteristics	Baseline	After six months
Age (mean, SD)	30.19 (9.14)	30.69 (9.75)
Male sex		14 (51.9%)
Atopy		27 (100%)
AD onset in years (mean, SD)		3.3 (1,4)
Eosinophils (mean, SD)	262 (302)	234 (332)
Total IgE (mean, SD)	536 (53)	539 (58)
DLQI (mean, SD)	17.7 (2.9)	12.7 (6.48) *
DLQI ≤ 6 points	0	13
ADCT (mean, SD)	16.4 (4.6)	8.89 (5.98) *
ADCT ≤ 6 points	0	13
Pruritus	8 (3.4)	5 (2.3) *
SCORAD (mean, SD)	37.5 (11.71)	25 (17.2) *
Patients SCORAD ≤ 20 points	0	13
Patients SCORAD75%	N/A	13
Patients SCORAD90%	N/A	10
Adverse events	N/A	14
<i>Severe</i>	N/A	0
<i>Gastrointestinal</i>	N/A	4
<i>Respiratory infections</i>	N/A	6
<i>Other</i>	N/A	4

Clinical and sociodemographic characteristics of patients before and after six months with baricitinib. Atopy was defined as one positive specific IgE. Pruritus was defined according to a subjective scale from 0 (no pruritus) to 10 (intense pruritus). SCORAD: Score atopic dermatitis, DLQI; Dermatology life quality index, and ADCT; Atopic dermatitis control tests. N/A; No apply. * $p < 0.05$.

Figure 1. Clinical response to Baricitinib and factors associated.



A: Score obtained according to the SCORAD (Score atopic dermatitis), DLQI (Dermatology life quality index), and ADCT (Atopic dermatitis control test) scales. In the first six months, follow-up is presented for all patients (n= 27) but from month 6 onwards, only those who had clinical control with Baricitinib are presented. **B:** Exploration of the variables associated with clinical control with Baricitinib according to Odds ratio.